In a recent article Levy (1951) records the treatment with an anti-histamine (Phenergan) of a small number of cases of infective arthritis and arthritis in Reiter's disease treated in a military hospital in Singapore. In his series of seven cases, six had a recent previous history of purulent urethritis, one having pyuria in addition, and the seventh had a recent previous history of bacillary dysentery and had developed the classical symptoms of Reiter's disease. Clinical improvement in the joints appeared in all cases in 7 days on a dosage of 150 mg. Phenergan daily, and all cases eventually returned to duty. Four of the patients had erythrocyte sedimentation rates varying from 46 to 97 mm. in one hour, and these all returned to normal at intervals varying from 21 days upwards. Broadly speaking, these cases had one aetiological factor in common, namely, a recent or present frank bacterial infection. This factor does not obtain in the aetiology of rheumatoid arthritis, but in view of the uniformly satisfactory results in these cases it was considered that the effect of Phenergan should be ascertained.
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Method
Assessment of the results in the series recorded in this paper was confined to noting variations in the degree of pain, swelling, range of joint movement, and blood sedimentation rate at the beginning and end of the course of treatment. These limitations were imposed partly because the investigation was carried out in a small hospital where facilities for more elaborate records are not immediately to hand, partly because the assessment was regarded in the light of a pilot experiment which could be amplified if the results justified it, and mainly because variation in these four factors is the basic test of any treatment of arthritis of the rheumatoid type.
Material Cases 1 to 9 had had rheumatoid arthritis for periods from 18 months upwards, and all were active during the period of the test, as will be noted from the blood sedimentation rate figures at the commencement of treatment. Joint conditions varied from soft tissue swelling to gross anatomical deformity, and all had some impairment of range of movement in at least one joint and pain in some degree. These cases were in-patients.
Cases 10 and 11 were out-patients living at a distance from the clinic, so that it was not practicable to record variations in signs and symptoms. Case 10 was, in point of fact, diagnosed later as gout, but Case 11 was undoubtedly suffering from rheumatoid arthritis. The common factor in both these latter cases was the presence of psoriasis. Dosage The results recorded in Levy's series were obtained with a daily dosage of 150 mg. over a period of 7 days, but it was considered that in the rheumatoid series the duration should be at least 21 days and that larger amounts should be employed if possible. Treatment was therefore begun with 100 mg. daily to ascertain whether any patient had an idiosyncrasy, and the dosage was thereafter rapidly increased to 150 mg. daily and then to 200 mg. at which level it was maintained until the 21 st day.
The only exceptions to this schedule were Case 8 where nausea and general discomfort compelled us to stop treatment at the 14th day, and Case 9 where the maximum was 250 mg. daily, which was continued for the last 10 days of the investigation. The results are shown in the Table. Discussion It will be observed that, although there was some improvement in subjective symptoms, eight cases had either no objective change or an actual deterioration. The most striking feature was the blood sedimentation rate, which showed a significant alteration only in Case 4. This case had been on treatment with myocrisin and the blood sedimentation rate was already dropping before treatment with Phenergan was commenced. The relief of pain experienced in a number of cases had been anticipated, owing to the slight analgesic action of Phenergan. Apart from the symptoms already noted in Case 8, no other effects were seen except a certain amount of somnolence and 
